133 related articles for article (PubMed ID: 38709562)
1. Single-Cell Transcriptional Signatures of Glomerular Disease in Transgenic Mice with APOL1 Variants.
Yoshida T; Latt KZ; Santo BA; Shrivastav S; Zhao Y; Fenaroli P; Chung JY; Hewitt SM; Tutino VM; Sarder P; Rosenberg AZ; Winkler CA; Kopp JB
J Am Soc Nephrol; 2024 May; ():. PubMed ID: 38709562
[No Abstract] [Full Text] [Related]
2. APOL1 kidney risk variants in glomerular diseases modeled in transgenic mice.
Yoshida T; Latt KZ; Santo BA; Shrivastav S; Zhao Y; Fenaroli P; Chung JY; Hewitt SM; Tutino VM; Sarder P; Rosenberg AZ; Winkler CA; Kopp JB
bioRxiv; 2023 Mar; ():. PubMed ID: 37090576
[No Abstract] [Full Text] [Related]
3. Transgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice.
Beckerman P; Bi-Karchin J; Park AS; Qiu C; Dummer PD; Soomro I; Boustany-Kari CM; Pullen SS; Miner JH; Hu CA; Rohacs T; Inoue K; Ishibe S; Saleem MA; Palmer MB; Cuervo AM; Kopp JB; Susztak K
Nat Med; 2017 Apr; 23(4):429-438. PubMed ID: 28218918
[TBL] [Abstract][Full Text] [Related]
4. Evolution of the primate trypanolytic factor APOL1.
Thomson R; Genovese G; Canon C; Kovacsics D; Higgins MK; Carrington M; Winkler CA; Kopp J; Rotimi C; Adeyemo A; Doumatey A; Ayodo G; Alper SL; Pollak MR; Friedman DJ; Raper J
Proc Natl Acad Sci U S A; 2014 May; 111(20):E2130-9. PubMed ID: 24808134
[TBL] [Abstract][Full Text] [Related]
5. Lessons From APOL1 Animal Models.
Yoshida T; Latt KZ; Heymann J; Kopp JB
Front Med (Lausanne); 2021; 8():762901. PubMed ID: 34765626
[TBL] [Abstract][Full Text] [Related]
6. APOL1 risk allele RNA contributes to renal toxicity by activating protein kinase R.
Okamoto K; Rausch JW; Wakashin H; Fu Y; Chung JY; Dummer PD; Shin MK; Chandra P; Suzuki K; Shrivastav S; Rosenberg AZ; Hewitt SM; Ray PE; Noiri E; Le Grice SFJ; Hoek M; Han Z; Winkler CA; Kopp JB
Commun Biol; 2018; 1():188. PubMed ID: 30417125
[No Abstract] [Full Text] [Related]
7. Inaxaplin for Proteinuric Kidney Disease in Persons with Two
Egbuna O; Zimmerman B; Manos G; Fortier A; Chirieac MC; Dakin LA; Friedman DJ; Bramham K; Campbell K; Knebelmann B; Barisoni L; Falk RJ; Gipson DS; Lipkowitz MS; Ojo A; Bunnage ME; Pollak MR; Altshuler D; Chertow GM;
N Engl J Med; 2023 Mar; 388(11):969-979. PubMed ID: 36920755
[TBL] [Abstract][Full Text] [Related]
8. APOL1 renal risk variants exacerbate podocyte injury by increasing inflammatory stress.
Wakashin H; Heymann J; Roshanravan H; Daneshpajouhnejad P; Rosenberg A; Shin MK; Hoek M; Kopp JB
BMC Nephrol; 2020 Aug; 21(1):371. PubMed ID: 32854642
[TBL] [Abstract][Full Text] [Related]
9. Antisense oligonucleotides ameliorate kidney dysfunction in podocyte-specific APOL1 risk variant mice.
Yang YW; Poudel B; Frederick J; Dhillon P; Shrestha R; Ma Z; Wu J; Okamoto K; Kopp JB; Booten SL; Gattis D; Watt AT; Palmer M; Aghajan M; Susztak K
Mol Ther; 2022 Jul; 30(7):2491-2504. PubMed ID: 35450819
[TBL] [Abstract][Full Text] [Related]
10. Recessive, gain-of-function toxicity in an APOL1 BAC transgenic mouse model mirrors human APOL1 kidney disease.
McCarthy GM; Blasio A; Donovan OG; Schaller LB; Bock-Hughes A; Magraner JM; Suh JH; Tattersfield CF; Stillman IE; Shah SS; Zsengeller ZK; Subramanian B; Friedman DJ; Pollak MR
Dis Model Mech; 2021 Aug; 14(8):. PubMed ID: 34350953
[TBL] [Abstract][Full Text] [Related]
11. Profiling
Liu E; Radmanesh B; Chung BH; Donnan MD; Yi D; Dadi A; Smith KD; Himmelfarb J; Li M; Freedman BS; Lin J
Kidney360; 2020 Mar; 1(3):203-215. PubMed ID: 32656538
[TBL] [Abstract][Full Text] [Related]
12. Apolipoprotein L1 (APOL1) cation current in HEK-293 cells and in human podocytes.
Vandorpe DH; Heneghan JF; Waitzman JS; McCarthy GM; Blasio A; Magraner JM; Donovan OG; Schaller LB; Shah SS; Subramanian B; Riella CV; Friedman DJ; Pollak MR; Alper SL
Pflugers Arch; 2023 Mar; 475(3):323-341. PubMed ID: 36449077
[TBL] [Abstract][Full Text] [Related]
13. APOL1 renal risk variants promote cholesterol accumulation in tissues and cultured macrophages from APOL1 transgenic mice.
Ryu JH; Ge M; Merscher S; Rosenberg AZ; Desante M; Roshanravan H; Okamoto K; Shin MK; Hoek M; Fornoni A; Kopp JB
PLoS One; 2019; 14(4):e0211559. PubMed ID: 30998685
[TBL] [Abstract][Full Text] [Related]
14. APOL1-G0 or APOL1-G2 Transgenic Models Develop Preeclampsia but Not Kidney Disease.
Bruggeman LA; Wu Z; Luo L; Madhavan SM; Konieczkowski M; Drawz PE; Thomas DB; Barisoni L; Sedor JR; O'Toole JF
J Am Soc Nephrol; 2016 Dec; 27(12):3600-3610. PubMed ID: 27026370
[TBL] [Abstract][Full Text] [Related]
15. Roles of APOL1 G1 and G2 variants in sickle cell disease patients: kidney is the main target.
Kormann R; Jannot AS; Narjoz C; Ribeil JA; Manceau S; Delville M; Joste V; Prié D; Pouchot J; Thervet E; Courbebaisse M; Arlet JB
Br J Haematol; 2017 Oct; 179(2):323-335. PubMed ID: 28699644
[TBL] [Abstract][Full Text] [Related]
16. APOL1 Risk Alleles Are Associated with Exaggerated Age-Related Changes in Glomerular Number and Volume in African-American Adults: An Autopsy Study.
Hoy WE; Hughson MD; Kopp JB; Mott SA; Bertram JF; Winkler CA
J Am Soc Nephrol; 2015 Dec; 26(12):3179-89. PubMed ID: 26038529
[TBL] [Abstract][Full Text] [Related]
17. APOL1-associated glomerular disease among African-American children: a collaboration of the Chronic Kidney Disease in Children (CKiD) and Nephrotic Syndrome Study Network (NEPTUNE) cohorts.
Ng DK; Robertson CC; Woroniecki RP; Limou S; Gillies CE; Reidy KJ; Winkler CA; Hingorani S; Gibson KL; Hjorten R; Sethna CB; Kopp JB; Moxey-Mims M; Furth SL; Warady BA; Kretzler M; Sedor JR; Kaskel FJ; Sampson MG
Nephrol Dial Transplant; 2017 Jun; 32(6):983-990. PubMed ID: 27190333
[TBL] [Abstract][Full Text] [Related]
18. Antisense oligonucleotide treatment ameliorates IFN-γ-induced proteinuria in APOL1-transgenic mice.
Aghajan M; Booten SL; Althage M; Hart CE; Ericsson A; Maxvall I; Ochaba J; Menschik-Lundin A; Hartleib J; Kuntz S; Gattis D; Ahlström C; Watt AT; Engelhardt JA; Monia BP; Magnone MC; Guo S
JCI Insight; 2019 Jun; 4(12):. PubMed ID: 31217349
[TBL] [Abstract][Full Text] [Related]
19. APOL1 promotes endothelial cell activation beyond the glomerulus.
Carracedo M; Ericson E; Ågren R; Forslöw A; Madeyski-Bengtson K; Svensson A; Riddle R; Christoffersson J; González-King Garibotti H; Lazovic B; Hicks R; Buvall L; Fornoni A; Greasley PJ; Lal M
iScience; 2023 Jun; 26(6):106830. PubMed ID: 37250770
[TBL] [Abstract][Full Text] [Related]
20. Association of APOL1 variants with mild kidney disease in the first-degree relatives of African American patients with non-diabetic end-stage renal disease.
Freedman BI; Langefeld CD; Turner J; Núñez M; High KP; Spainhour M; Hicks PJ; Bowden DW; Reeves-Daniel AM; Murea M; Rocco MV; Divers J
Kidney Int; 2012 Oct; 82(7):805-11. PubMed ID: 22695330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
